nach oben

Current Cardiology Reports

Erschienen in:

01.06.2019 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

verfasst von: Thwe Htay, Kyaw Soe, Arianna Lopez-Perez, Amy HoangAnh Doan, Michael A. Romagosa, KoKo Aung

Erschienen in: Current Cardiology Reports | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aims of this review are to summarize recent data on mortality and cardiovascular disease (CVD) in type 1 and type 2 diabetes and to determine the interventions that could have contributed to a reduction in mortality.

Recent Findings

Recent studies found a downward trend in mortality and CVD among both diabetics and non-diabetics worldwide over the last few decades. The decline among diabetics is steeper than that among non-diabetics. Despite a parallel trend of decline, an approximately twofold difference in mortality and CVD between the two populations remains.

Summary

A greater emphasis on glycemic control, management of cardiovascular risk factors, quality improvement programs, and advances in treatment of conditions associated diabetes are the factors that potentially contributed to the improvement. Although the trend is encouraging, a rising prevalence of diabetes will continue the absolute disease burden to the society. Future interventions should focus on prevention of diabetes.

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.CrossRef

•• Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017. A periodic publication of the United States Centers for Disease Control and Prevention (CDC) that provides updated statistics about diabetes in the United States for a scientific audience.

Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(Suppl 2):S14–21.CrossRef

Chaib F. New WHO statistics highlight increases in blood pressure and diabetes, other noncommunicable risk factors, 2012. World Health Organization: Noncommunicable Diseases and Mental Health.

Vaidya V, Gangan N, Sheehan J. Impact of cardiovascular complications among patients with type 2 diabetes mellitus: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):487–97. https://doi.org/10.1586/14737167.2015.1024661.CrossRefPubMed

Kovacic JC, Castellano JM, Farkouh ME, Fuster V. The relationships between cardiovascular disease and diabetes: focus on pathogenesis. Endocrinol Metab Clin N Am. 2014;43(1):41–57. https://doi.org/10.1016/j.ecl.2013.09.007.CrossRef

Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91. https://doi.org/10.1056/NEJMoa0706245.CrossRefPubMed

Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet (London, England). 2012;379(9833):2252–61. https://doi.org/10.1016/s0140-6736(12)60480-2.CrossRef

•• Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–18. https://doi.org/10.1056/NEJMoa1608664 Trends in deaths and cardiovascular events among patients with type 1 diabetes and type 2 diabetes from the Swedish National Diabetes Register from 1998 to 2014 compared with matched controls. CrossRefPubMed

10.

•• Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet (London, England). 2018;391(10138):2430–40. https://doi.org/10.1016/s0140-6736(18)30314-3 Trends in total mortality and cause-specific mortality, including cardiovascular mortality, among adults with diabetes from the US National Health Interview Survey Linked Mortality files from 1998–1994 through 2010–2015 compared with adults without diabetes. CrossRef

11.

Dabelea D, Bell RA, D'Agostino RB Jr, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. Jama. 2007;297(24):2716–24. https://doi.org/10.1001/jama.297.24.2716.CrossRefPubMed

12.

•• Secrest AM, Washington RE, Orchard TJ. Mortality trends in type 1 diabetes. Chapter 35, In Diabetes in America, 3rd ed. Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, Eds. Bethesda, MD, National Institutes of Health, NIH Pub No. 17–1468, 2018:35–1 – 35-16. A report published by the US National Institute of Diabetes and Digestive and Kidney Diseases, which analyzes mortality trends and investigates risk factors for a higher mortality in individuals with type 1 diabetes than general population.

13.

Diabetes death rates among youths aged </= 19 years--United States, 1968–2009. MMWR Morbidity and mortality weekly report. 2012;61(43):869–72.

14.

•• Petrie D, Lung TW, Rawshani A, Palmer AJ, Svensson AM, Eliasson B, et al. Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia. 2016;59(6):1167–76. https://doi.org/10.1007/s00125-016-3914-7 Analysis of data from the Swedish National Diabetes Register linked with death records to assess trends in overall and cause-specific mortality for individuals with type 1 diabetes. CrossRefPubMed

15.

•• Rosenquist KJ, Fox CS. Chapter 36, In Diabetes in America, 3rd ed. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Mortality trends in type 2 diabetes. Bethesda, MD: National Institutes of Health, NIH Pub No. 17–1468; 2018. p. 36–1–36-14. A report published by the US National Institute of Diabetes and Digestive and Kidney Diseases, which analyzes mortality trends and investigates risk factors for a higher mortality in individuals with type 2 diabetes than in general population.

16.

Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med. 2007;147(3):149–55.CrossRef

17.

Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB Sr, Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119(13):1728–35. https://doi.org/10.1161/circulationaha.108.829176.CrossRefPubMedPubMedCentral

18.

Taylor KS, Heneghan CJ, Farmer AJ, Fuller AM, Adler AI, Aronson JK, et al. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013;36(8):2366–71. https://doi.org/10.2337/dc12-1513.CrossRefPubMedPubMedCentral

19.

•• Bragg F, Holmes MV, Iona A, Guo Y, Du H, Chen Y, et al. Association between diabetes and cause-specific mortality in rural and urban areas of China. Jama. 2017;317(3):280–9. https://doi.org/10.1001/jama.2016.19720 A population study that uses national survey data to compare the prevalence of diabetes and to provide estimates of the diabetes-related excess mortality for adults living in rural and urban areas of China. CrossRefPubMedPubMedCentral

20.

McEwen LN, Karter AJ, Waitzfelder BE, Crosson JC, Marrero DG, Mangione CM, et al. Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care. 2012;35(6):1301–9. https://doi.org/10.2337/dc11-2281.CrossRefPubMedPubMedCentral

21.

Koek HL, Soedamah-Muthu SS, Kardaun JW, Gevers E, de Bruin A, Reitsma JB, et al. Short- and long-term mortality after acute myocardial infarction: comparison of patients with and without diabetes mellitus. Eur J Epidemiol. 2007;22(12):883–8. https://doi.org/10.1007/s10654-007-9191-5.CrossRefPubMedPubMedCentral

22.

Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59(12):3216–22. https://doi.org/10.2337/db10-0862.CrossRefPubMedPubMedCentral

23.

Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, et al. The British Diabetic Association Cohort Study, I: all-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med. 1999;16(6):459–65.CrossRef

24.

•• Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet (London, England). 2018;392(10146):477–86. https://doi.org/10.1016/s0140-6736(18)31506-x A nationwide register-based cohort study in Sweden examining how age at diagnosis of type 1 diabetes relates to excess mortality and cardiovascular risk. CrossRef

25.

Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB Sr, et al. Trends in cardiovascular complications of diabetes. Jama. 2004;292(20):2495–9. https://doi.org/10.1001/jama.292.20.2495.CrossRefPubMed

26.

Booth GL, Kapral MK, Fung K, Tu JV. Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care. 2006;29(1):32–7.CrossRef

27.

•• Tsujimoto T, Kajio H, Sugiyama T. Favourable changes in mortality in people with diabetes: US NHANES 1999–2010. Diabetes Obes Metab. 2018;20(1):85–93. https://doi.org/10.1111/dom.13039 Trends in total, cardiovascular, and cardiac mortality in diabetics participated in the US National Health and Nutrition Examination Survey during the period 2005 to 2010 and comparison with participants without diabetes. CrossRefPubMed

28.

Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514–23. https://doi.org/10.1056/NEJMoa1310799.CrossRefPubMed

29.

•• Burrows NR, Li Y, Gregg EW, Geiss LS. Declining rates of hospitalization for selected cardiovascular disease conditions among adults aged >/=35 years with diagnosed diabetes, U.S., 1998-2014. Diabetes Care. 2018;41(2):293–302. https://doi.org/10.2337/dc17-1259 Trend analyses of age-adjusted hospitalization rates for specific cardiovascular conditions using the National Inpatient Sample data of the US Agency for Healthcare Research and Quality. CrossRefPubMed

30.

•• Jung CH, Chung JO, Han K, Ko SH, Ko KS, Park JY. Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006–2013). Cardiovasc Diabetol. 2017;16(1):1. https://doi.org/10.1186/s12933-016-0482-6 Eight-year trend of cardiovascular disease in Korean adults with type 2 diabetes, aged 30 years and older, using data from four consecutive nationwide databases of Korean national health insurance service. CrossRefPubMedPubMedCentral

31.

Kim HC, Oh SM. Noncommunicable diseases: current status of major modifiable risk factors in Korea. J Prev Med Public Health. 2013;46(4):165–72. https://doi.org/10.3961/jpmph.2013.46.4.165.CrossRefPubMedPubMedCentral

32.

•• de Miguel-Yanes JM, Jimenez-Garcia R, Hernandez-Barrera V, Mendez-Bailon M, de Miguel-Diez J, Lopez-de-Andres A. Impact of type 2 diabetes mellitus on in-hospital-mortality after major cardiovascular events in Spain (2002–2014). Cardiovasc Diabetol. 2017;16(1):126. https://doi.org/10.1186/s12933-017-0609-4 A retrospective nationwide register-based study in Spain examining the trends in number of cases and outcomes, in-hospital mortality, and length of hospital stay for major cardiovascular events in individuals with type 2 diabetes compared with non-diabetics. CrossRefPubMedPubMedCentral

33.

U.S. Food and Drug Administration. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. In: Fda.gov; 2018. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 31 Oct 2018

34.

Azimova K, San Juan Z, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J. 2014 Winter;14(4):616–32.PubMedPubMedCentral

35.

•• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827 A randomized controlled trial assessing long-term effects of liraglutide on cardiovascular outcomes in individuals with type 2 diabetes. CrossRefPubMedPubMedCentral

36.

• Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. https://doi.org/10.1056/NEJMoa1509225 A randomized controlled trial assessing the effects of lixisenatide on cardiovascular outcomes in individuals with type 2 diabetes who had had a recent acute coronary event. CrossRefPubMed

37.

• Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720 A randomized controlled trial assessing effects of empagliflozin on cardiovascular morbidity and mortality in individuals with type 2 diabetes at high cardiovascular risk. CrossRefPubMed

38.

•• Saad M, Mahmoud AN, Elgendy IY, Abuzaid A, Barakat AF, Elgendy AY, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol. 2017;228:352–8. https://doi.org/10.1016/j.ijcard.2016.11.181 A meta-analysis of randomized controlled trials assessing the effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in individuals with type 2 diabetes. CrossRefPubMed

39.

•• American Diabetes Association: 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes care. 2018;41(Suppl 1):S86-s104. https://doi.org/10.2337/dc18-S009. The American Diabetes Association’s standards of medical care in diabetes related to cardiovascular risk reduction.

Titel: Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
verfasst von: Thwe Htay
Kyaw Soe
Arianna Lopez-Perez
Amy HoangAnh Doan
Michael A. Romagosa
KoKo Aung
Publikationsdatum: 01.06.2019
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 6/2019
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-019-1133-9

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Dyslipidemia Profiles in Patients with Peripheral Artery Disease

Lifestyle Interventions to Prevent Cardiovascular Events After Stroke and Transient Ischemic Attack

Psychosocial Factors and Recovery After Acute Myocardial Infarction in Younger Women

Use of Cardiac Imaging to Evaluate Cardiac Function and Pulmonary Hemodynamics in Patients with Heart Failure